Patricia Imms

Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.

Anu Asnaani, Andrew B. Schmidt, E. Foa, 2022, JAMA psychiatry.

Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial.

D. Oslin, E. Foa, J. Volpicelli, 2013, JAMA.

Concurrent Varenicline and Prolonged Exposure for Patients With Nicotine Dependence and PTSD: A Randomized Controlled Trial

Anu Asnaani, E. Foa, P. Gariti, 2017, Journal of consulting and clinical psychology.

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Mark B. Powers, Monnica T. Williams, M. Liebowitz, 2013, JAMA psychiatry.

Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.

Mark B. Powers, Monnica T. Williams, M. Liebowitz, 2015, The Journal of clinical psychiatry.

Maximizing remission from cognitive-behavioral therapy in medicated adults with obsessive-compulsive disorder.

Anu Asnaani, Andrew B. Schmidt, E. Foa, 2021, Behaviour research and therapy.

Are People Hesitating—Or Just Postponing—to Get the Covid-19 Vaccine? Vaccine Outreach in Marginalized Urban Communities

Lauren Kogen, Kathleen Reeves, Patricia Imms, 2022, The American Behavioral Scientist.

Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.

Mark B. Powers, Monnica T. Williams, M. Liebowitz, 2013, JAMA psychiatry.